Pharmacokinetic and pharmacodynamic evaluation of macitentan, a novel endothelin receptor antagonist for the treatment of pulmonary arterial hypertension-Reference-Cited by-同舟云学术

Pharmacokinetic and pharmacodynamic evaluation of macitentan, a novel endothelin receptor antagonist for the treatment of pulmonary arterial hypertension

Published:2015-01-21 Issue:3 Volume:11 Page:437-449
ISSN:1742-5255
Container-title:Expert Opinion on Drug Metabolism & Toxicology
language:en
Short-container-title:Expert Opinion on Drug Metabolism & Toxicology

Author:

Sidharta Patricia N,Krähenbühl Stephan,Dingemanse Jasper

Publisher

Informa Healthcare

Subject

Pharmacology,Toxicology,General Medicine

Link

http://www.tandfonline.com/doi/pdf/10.1517/17425255.2015.1000859

Reference97 articles.

1. Guidelines for the diagnosis and treatment of pulmonary hypertension

2. Updated Treatment Algorithm of Pulmonary Arterial Hypertension

3. Survival in Patients with Primary Pulmonary Hypertension

4. Survival in Patients With Idiopathic, Familial, and Anorexigen-Associated Pulmonary Arterial Hypertension in the Modern Management Era

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Study on the comparison between Bosentan and Macitentan in the treatment of persistent pulmonary hypertension of the newborns, simultaneously on sildenafil: A randomized double-blinded non-inferiority parallel clinical trial;Pediatrics & Neonatology;2024-05

2. New Therapy Update Aprocitentan: An Endothelin Receptor Antagonist for the Treatment of Drug-Resistant Systemic Hypertension;Cardiology in Review;2023-08-02

3. Long‐term safety of macitentan in patients with pulmonary hypertension: A meta‐analysis of randomised controlled trials;European Journal of Clinical Investigation;2023-07

4. Endothelin Receptor Antagonists in Kidney Disease;International Journal of Molecular Sciences;2023-02-08

5. Macitentan: An overview of its degradation products, process-related impurities, and in silico toxicity.;Computational Toxicology;2023-02